- Novartis will present 34 abstracts from leading MS portfolio, including the highly anticipated results from the Phase III trial of investigational B-cell therapy ofatumumab (OMB157), data for Mayzent (siponimod) and Gilenya (fingolimod)
- Results from head-to-head Phase III ASCLEPIOS studies evaluating efficacy and safety of ofatumumab, an investigational B-cell therapy that potentially can be administered subcutaneously at home by patients with relapsing multiple sclerosis, will be presented for the first time
- Additional EXPAND data support that patients benefit from Mayzent treatment, which has a positive impact on cognition and prolonged mobility[2-4]
- New data on neurofilaments and glial fibrillary acidic protein support their use as potential clinical biomarkers of disease activity, treatment response and disability progression, helping to pave the way to introduce new monitoring instruments beyond MRI[5,6]
Basel, September 10, 2019 - Novartis, a global leader in neuroscience, announced today it will present 34 abstracts at the upcoming 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 11-13, 2019 in Stockholm, Sweden. The breadth of data being presented highlights the company’s commitment to improving the lives of people living with MS, no matter where they are in their disease journey.
"We are excited to be presenting new data at ECTRIMS from across our unique portfolio and demonstrating how we are leading the way in reimagining MS care," said Danny Bar-Zohar, Global Head, Neuroscience Development for Novartis Pharmaceuticals. "Novartis is dedicated to advancing the science and developing transformative medicines so that we can solve the significant unmet needs that still exist in the treatment of MS."